Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris Inc. (NASDAQ: VTRS) has been ranked fifth on Fortune's Change the World list, recognizing its positive societal impact through healthcare initiatives. The company was acknowledged for expanding access to HIV medications in low- and middle-income countries via public-private partnerships. Key achievements include introducing a low-cost dolutegravir regimen for $75 per year and a pediatric version at a 75% reduced cost, promoting affordable treatment. Viatris serves over 40% of global HIV patients and emphasizes its commitment to social responsibility and innovative healthcare solutions.

Viatris reported Q2 2021 revenues of $4.58 billion with a GAAP net loss of $279 million. Adjusted EBITDA stood at $1.68 billion, while net cash from operating activities was $559 million and free cash flow reached $470 million. The company raised its full-year guidance: total revenues are now expected to be between $17.5 billion and $17.9 billion, adjusted EBITDA between $6.15 billion and $6.45 billion, and free cash flow between $2.2 billion and $2.4 billion. Additionally, a quarterly dividend of $0.11 per share was declared, and $1.15 billion of debt was paid down in H1 2021.

Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. announced the FDA approval of Semglee® (insulin glargine-yfgn injection) as the first interchangeable biosimilar under the 351(k) pathway. This approval allows Semglee to be substituted for Lantus® at pharmacies and is expected to enhance access to diabetes treatment. The companies will launch Semglee by the end of the year and may enjoy 12 months of exclusivity before competing biosimilars can enter the market. This significant milestone reflects Viatris’ scientific capabilities and commitment to increasing patient access to complex treatments.

Viatris (NASDAQ: VTRS) announced that the U.S. District Court for Kansas dismissed a lawsuit filed by KPH Healthcare Services, asserting claims against Mylan and Pfizer over EpiPen products. The court ruled that KPH lacked legal standing, allowing the case to be dismissed entirely, with a possibility for KPH to file a limited amended complaint within 30 days. Viatris expressed satisfaction with the ruling, emphasizing its commitment to legal compliance and willingness to defend against future proceedings.

Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2021 financial results on August 9, before the U.S. market opens. A webcast featuring CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will be held at 10 a.m. ET the same day. Investors can listen to the call live via the company's investor website or by phone. Established in November 2020, Viatris focuses on providing access to medicines and healthcare solutions globally, maintaining a portfolio of over 1,400 approved molecules.

Viatris (NASDAQ: VTRS) will participate in a virtual fireside chat at the Goldman Sachs 42^nd Annual Global Healthcare Conference on June 10, 2021, at 10:30 a.m. ET. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will discuss the company and address queries. Interested individuals can access the live webcast at investor.viatris.com, with an archived version available later. Viatris aims to empower global health through access to over 1,400 medicines and operates in 165 countries.

Viatris Inc. (VTRS) reported Q1 2021 financial results with total revenue at $4.4 billion, reflecting a 70% increase year-over-year. The company faced a U.S. GAAP net loss of $1.0 billion, while adjusted EBITDA stood at $1.6 billion. Free cash flow reached $799 million. The Board declared a quarterly dividend of $0.11 per share, payable June 26, 2021. Viatris anticipates achieving approximately $500 million in synergies and has generated $163 million from new product revenue, reiterating its positive outlook for the year.

Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 9:10 a.m. ET. CEO Michael Goettler and CFO Sanjeev Narula will discuss the company and answer questions. A live webcast will be available at investor.viatris.com, with an archived version accessible later. Formed in November 2020 from Mylan and Pfizer's Upjohn business, Viatris serves over 165 countries and offers a diverse portfolio of over 1,400 approved medicines.